As high-throughput genomics and its postgenomics successor, proteomics, are the technologies of choice for rapid screening of new pharmaceuticals, a company that establishes itself as a technology leader in both fields could be ahead of the pack: New Haven, Conn.-based Molecular Staging (MSI).
In November 2002, MSI announced in rapid succession that 1) it received a Small Business Innovation Research (SBIR) grant from the US Department of Energy's Genomes to Life program to develop MSI's multiple displacement amplification (MDA) technology for DNA amplification and identification of microbes; 2) its REPLI-g™ Whole Genome Amplification kits are now available; and 3) it received an SBIR award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, to develop a chip that detects osteoarthritis protein biomarkers.
REPLI-g is a line of kits that make whole genome amplification (WGA) easier and faster. MSI's chief operating officer Stephen Kingsmore explains that the kits come ...
